<SEC-DOCUMENT>0001493152-21-017694.txt : 20211129
<SEC-HEADER>0001493152-21-017694.hdr.sgml : 20211129
<ACCEPTANCE-DATETIME>20210723212915
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001493152-21-017694
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20210723

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Biofrontera Inc.
		CENTRAL INDEX KEY:			0001858685
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				473765675
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		120 PRESIDENTIAL WAY,
		STREET 2:		SUITE 330
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801
		BUSINESS PHONE:		781-245-1325

	MAIL ADDRESS:	
		STREET 1:		120 PRESIDENTIAL WAY,
		STREET 2:		SUITE 330
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><IMG SRC="corresp_001.jpg" ALT="" STYLE="height: 115px; width: 242px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; color: #082253"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biofrontera
Inc &middot; 120 Presidential Way, Suite 330 &middot; Woburn, MA 01801 &middot; USA</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VIA
EDGAR AND EMAIL</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
23, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
and Exchange Commission</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Division
of Corporation Finance</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
of Life Sciences</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100
F Street, N.E.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington,
D.C. 20549</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abby
    Adams</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suzanne
    Hayes</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tara
    Harkins</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    Cascio</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Re:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Biofrontera
    Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
    Statement on Form S-1</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed
    July 6, 2021</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>File
    No. 333-257722</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are submitting this letter in response to the comment letter, dated July 19, 2021, of the staff of the Division of Corporation Finance
(the &ldquo;<B>Staff</B>&rdquo;) of the Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;) with respect to the
above-referenced filing. This letter and our Amendment No. 1 to the Registration Statement on Form S-1 (the &ldquo;<B>Amendment No. 1</B>&rdquo;)
are being filed with the Commission electronically today. In addition to the electronic filing, we are delivering via email a copy of
this letter, along with a courtesy copy of the Amendment No. 1 marked to indicate changes from the Registration Statement filed on July
6, 2021. In addition to addressing the comments raised by the Staff in its letter, we have revised the Amendment No. 1 to update other
disclosures. Each of our responses is set forth in ordinary type beneath the corresponding Staff comment, which is set out in bold type.
The page references in our responses are to the pages in the marked version of the Amendment No. 1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Registration
Statement on Form S-1 filed on July 6, 2021</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Management&rsquo;s
Discussion and Analysis of Financial Discussion and Results of Operations Selling, General and Administrative Expenses, Related Party,
page 51</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Refer
    to comment 9 of our June 6, 2021, letter. We note you filed the Master Contract Services Agreement dated July 2, 2021 by and among
    the Company, Biofrontera AG, Biofrontera Pharma GmbH and Biofrontera Bioscience GmbH as Exhibit 10.8. Please revise the disclosure
    on page 51 and elsewhere, as applicable, to clarify this agreement extends the Intercompany Services Agreement and the Quality Assurance
    Agreement, both of which have expired by their terms, but appear to have been followed in practice and revived in this agreement,
    as reflected in paragraph 9.5 of this agreement. File both agreements as exhibits to the registration statement. If the agreements,
    in fact, do not apply, revise page 51 to clarify whether Biofrontera AG continues to provide your accounting consolidation, IT support
    and pharmacovigilance services, and if so, how those expenses are charged to you and under what agreement. This agreement appears
    to defer all allocations of expenses to be determined for at the time of each proposed statement of work.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Response</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
acknowledge the Staff&rsquo;s comment and respectfully advise the Staff that we have revised the disclosure on pages 2, 51, 75 and 101
of Amendment No. 1 to clarify the relationship between the Master Contract Services Agreement and the other intercompany agreements
we have entered into with the Biofrontera Group. We respectfully inform the Staff that the Master Contract Services Agreement does not
extend either the prior Intercompany Services Agreement or the Quality Assurance Agreement. The Master Contract Services Agreement is
meant to supersede the existing Intercompany Services Agreement as is indicated in the second paragraph of Section 9.5 of the Master
Contract Services Agreement. Section 9.5 of the Master Contract Services Agreement also states that the agreement is intended to be consistent
with the Amended and Restated License and Supply Agreement and the Quality Assurance Agreement and that to the extent there is any conflict
with those agreements, the terms of the Amended and Restated License and Supply Agreement, as applicable, should prevail. Since the Amended
and Restated License and Supply Agreement was recently entered into, it has not yet lapsed and, therefore, does not need to be extended
by the Master Contract Services Agreement. The Quality Assurance Agreement is by its terms intended to be a living document that evolves
with the Company&rsquo;s development and is tied to the Amended and Restated License and Supply Agreement. As a result, the Quality Assurance
Agreement relies on the Amended and Restated License and Supply Agreement to maintain its force, and it does not need to be extended
by the Master Contract Services Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
the Intercompany Services Agreement has been superseded by the Master Contract Services Agreement, we have not filed it as an exhibit
to Amendment No. 1. As requested by the Staff, we have filed the Quality Assurance Agreement as Exhibit 10.9 to Amendment No. 1, since
it will remain in effect following the initial public offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Business</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Our
Strategy, page 64</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
    note your response to comment 3. Clarify, for example, why this proposed transaction is more beneficial than, for example, structuring
    the spinoff differently, to provide the company more control of the future pipeline development than in the June 16, 2021 Ameluz
    LSA.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Response</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
acknowledge the Staff&rsquo;s comment and respectfully advise the Staff that we have revised the disclosure on page 65 to further elucidate
why a potential acquisition of a controlling interest in Biofrontera AG would be more beneficial to the Company than structuring the
spinoff differently. As discussed in greater detail on a call with the Staff on July 20, 2021, the post-IPO arrangements between the
Company and Biofrontera AG were the result of arm&rsquo;s-length negotiations with Biofrontera AG and reflect that Biofrontera AG would
not cede control of the product pipeline. However, we believe that, should the opportunity present itself, acquiring a controlling interest
of Biofrontera AG through a tender or exchange offer would provide benefits to shareholders of both companies. Nevertheless, such a potential
transaction would be subject to a number of conditions and the further actions that would need to be taken to satisfy those conditions
cannot be undertaken prior to the IPO and we will not be able to assess the feasibility of satisfying those conditions until after the
consummation of the initial public offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 88%"><P STYLE="margin-top: 0; margin-bottom: 0">Biofrontera Inc. &middot; 120 Presidential Way, Suite 330 &middot; Woburn, MA 01801
                                                                                                                                                                                                                                                      &middot; USA&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0">Contact Phone +1 781 245 1325 &middot; E-Mail info-us@biofrontera.com &middot; www.biofrontera.us.com</P><P STYLE="margin-top: 0; margin-bottom: 0">Board of Directors Prof. Dr. Hermann Luebbert (CEO &amp; Chair) &middot; Erica Monaco (CFO &amp; COO) </P></TD><TD STYLE="width: 12%; text-align: right">Page
                                            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 3</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you have any questions regarding this letter or the Registration Statement, please contact the undersigned at <U>e.monaco@biofrontera.com
</U>or (781) 486-1502.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours, </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biofrontera
    Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><I>/s/ Erica Monaco</I></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Erica
    Monaco</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer and Chief Operating Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cc:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hermann
    Luebbert</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Biofrontera
    Inc.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stephen
    Older</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>McGuireWoods
    LLP</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ralph
    De Martino</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Schiff
    Hardin LLP</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 88%"><P STYLE="margin-top: 0; margin-bottom: 0">Biofrontera Inc. &middot; 120 Presidential Way, Suite 330 &middot; Woburn, MA 01801
                                                                                                                                                                                                                                                      &middot; USA&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0">Contact Phone +1 781 245 1325 &middot; E-Mail info-us@biofrontera.com &middot; www.biofrontera.us.com</P><P STYLE="margin-top: 0; margin-bottom: 0">Board of Directors Prof. Dr. Hermann Luebbert (CEO &amp; Chair) &middot; Erica Monaco (CFO &amp; COO) </P></TD><TD STYLE="width: 12%; text-align: right">Page
                                            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> of 3</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>corresp_001.jpg
<TEXT>
begin 644 corresp_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "( 1\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D)
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M0!X7\4563XU>%D90RLEH"#T(^T/7LDVA:3<1-%+IUJZ,,%6B!!KQ+XQ+=O\
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"_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
